Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension
Trial Timeline
Oct 18, 2023 → Feb 28, 2026
NCT ID
NCT06041529About Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg is a approved stage product being developed by Yuhan for Essential Hypertension. The current trial status is active. This product is registered under clinical trial identifier NCT06041529. Target conditions include Essential Hypertension.
What happened to similar drugs?
14 of 20 similar drugs in Essential Hypertension were approved
Approved (14) Terminated (2) Active (6)
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06041529 | Approved | Active |
Competing Products
20 competing products in Essential Hypertension